Regeneron loses bid to scrap infringement lawsuit linked to COVID antibody cocktail

Pfizer and BioNTech recently emerged from a lawsuit unscathed after Allele Biotechnology and Pharmaceuticals cried patent infringement against a trio of pandemic juggernauts. For Regeneron, however, the legal battle is set to roll on.

Earlier this week, U.S. District Judge Philip Halpern shot down Regeneron’s bid to dismiss Allele’s lawsuit. The San Diego-based company claims Regeneron developed its COVID-19 antibody cocktail REGEN-COV using Allele’s fluorescent protein, mNeonGreen, without its permission.